Celera Genomics Signs Database Pact With Arena

URL: http://www.washtech.com/news/biotech/8320-1.html

Date accessed: 20 March 2001

Thursday, March 15, 2001
By Staff Reporter ,
Reuters

ROCKVILLE, Md.—Celera Genomics Group , a unit of Applera Corp., said on Thursday that Arena Pharmaceuticals Inc. has signed a multi-year subscription agreement to use Celera's databases for genomic research.

Financial terms were not disclosed for the accord on genomics research, which is the study of genes and their functions for drug development.

Under the deal, Arena researchers will use Celera's integrated database products, bioinformatics systems and other tools in conducting their genomics research. They will access Celera's products through the Web-based Celera Discovery System.

Shares of Celera, which sells databases describing genes and proteins of humans and of important lab organisms like the mouse and fruit fly, closed at $36.20 in New York Stock Exchange trading Wednesday, near the low end of $27.75 to $215.

Shares of drug developer Arena closed at $18-1/8 in Nasdaq market trading Wednesday. The stock has a 52-week range of $11-9/16 to $47.

© 2001 Reuters

© 2001 The Washington Post Company

Category: 52. Genetic Banks and Databases